clinical trials

News

Ascletis says oral acne drug shows "exceptional efficacy"

Phase 3 results for Ascletis' novel acne candidate have set up filings in China and bode well for a similar drug being developed by Sagimet in the US.

News

ASCO 25: Sanofi hopes on-body delivery will boost Sarclisa

Can a new on-body injector version of Sanofi's Sarclisa help it claim market share from J&J's rival top-selling Darzalex in multiple myeloma?

News

Gerhardt Attard of University College London

ASCO 25: J&J combo pill may see wider use in prostate cancer

AMPLITUDE study of J&J's Akeega could extend the use of PARP inhibitors to hormone-responsive prostate cancer.

News

ASCO 25: Enhertu bids for earlier use in HER2+ breast cancer

AstraZeneca and Daiichi Sankyo have revealed the data they hope will move Enhertu into frontline therapy for HER2-positive advanced breast cancer.

News

ASCO 25: AZ pitches upfront oral SERD use in breast cancer

AstraZeneca stakes a claim to first-line treatment of HR+ breast cancer with its oral SERD, as Arvinas/Pfizer reveal their second-line data.

News

ASCO 25: Gilead eyes first-line use of Trodelvy in TNBC

Gilead lays down a marker for AZ and Daiichi Sankyo to follow as Trodelvy scores in first-line treatment of triple-negative breast cancer (TNBC).

Ascletis says oral acne drug shows "exceptional efficacy"

ASCO 25: Sanofi hopes on-body delivery will boost Sarclisa

ASCO 25: J&J combo pill may see wider use in prostate cancer

ASCO 25: Enhertu bids for earlier use in HER2+ breast cancer

ASCO 25: AZ pitches upfront oral SERD use in breast cancer

ASCO 25: Gilead eyes first-line use of Trodelvy in TNBC

GBL joins CVC in €10.7bn takeover bid for Recordati

Discover a new era of healthcare panel engagement: Grounded ...

clinical trials

Editor's Picks